hakuna matata aint pass craze mean worri rest day
ceo mile white confid outlook eventu transit view two
lead concern invest commun sustain growth
inevit departur mile white serv compani chairman
ceo sinc call mr white note robert ford who
move role expect key leadership role long time
white said read line view mean ford heir
appar mr white went say investor nervou
leadership transit abbott pois perform well across board
year white see decad pretti robust growth
rais bar view abbott result impress organ sale
growth growth continu fuel freestyl libr continu blood
glucos monitor contribut overal top-lin growth well
alin diagnost system ytd perform gave manag confid
rais organ sale expect moreov manag
suggest level growth new norm manag also tighten
rais ep guidanc year weve updat
model weve rais
rais price target stick overweight rate go
quarter concern good get point
abbott prove us wrong stronger organ growth higher organ sale outlook
yet convinc sustain seem like
next coupl year opportun drive double-digit ep growth
believ above-average/p growth profil worthi premium multipl
updat pt valuat methodolog target pe use ep
current trade ep other compar growth trade
new pt appli prior pt risk
sustain growth specif outlook freestyl libr alin
quarterli annual ep usd
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
rais usd
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight view share high-
qualiti growth asset believ compani
favor mix busi product
geograph perspect see medic devic
busi particularli diabet key driver
growth go forward believ growth profil
upsid case depend sever key factor
strong growth libr alin approv
adopt new product particularli within medic
devic abil drive margin expans
downsid case driven slower
libre/alin sale fx slowdown emerg
market inabl receiv product approv and/or
acquisit sentiment around likelihood
view result impress organ sale growth better-than-expect
though report basi sale shi street estim
due greater-than-expect fx headwind ep streets/our
estim guidanc strong momentum expect
continu abbott rais full year organ sale growth guidanc
ep outlook see detail net/net view stock
chang abbott growth profil continu impress think stock
addit detail quarter
million except per share data chang sale constant currenc organ basi unless otherwis note
diabet sale y/i driven continu adopt growth
freestyl libr grew organ
quarter freestyl libr
contribut sale quarter contribut overal top-lin
growth y/i organ growth abbott expect fda approv libr
icgm rel soon
diagnost sale organ basi driven alin
structur heart grew strong mitraclip growth manag recent
receiv fda approv fourth gener mitraclip
manag increas full year growth guidanc bp
adjust full year ep guidanc
medic devic growth strong organ
segment weaker perform vascular rhythm manag
neuromodul
fx headwind greater expect
molecular diagnost continu pressur due non-
government purchas pattern africa
sale constant currenc organ basi
gross margin y/i capac expans weigh result
sg margin y/i margin flat y/i
adjust tax rate y/i mgmt guidanc around
full year tax rate expect lower
adjust ep street estim
abbott expect organ sale growth organ basi expect follow division/product area establish
pharma epd sale growth mid-to-high single-digit nutrit expect grow mid single-digit legaci diagnost
busi high single-digit rapid diagnost growth low-to-mid single-digit medic devic expect grow
high single-digit continu double-digit growth sever area fx expect headwind abbott expect ep
reflect doubl digit growth time earn releas street estim
abbott rais organ sale growth divis organ sale basi abbott expect epd growth
mid-to-high single-digit nutrit low-to-mid single-digit legaci diagnost mid-to-high single-digit
diagnost low-to-mid single-digit medic devic high single-digit fx expect neg
impact sale gross margin expect littl less versu somewhat due ramp-up alin
libr capac expans expect littl less sale sg expect around sale abbott
increas ep guidanc pre-releas street
model avail barclay live websit http //live barcap com/ upon request
actualsal laboratori management impact chang barclay abbott laboratori
kristen stewart cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
